The Global Institute for Novel Nicotine (GINN) is proud to announce a strategic partnership with Labstat International Inc., a renowned leader in nicotine product testing. This collaboration marks the formation of a steering committee within GINN on science and standards, aimed at advancing scientific research and establishing rigorous product and manufacturing standards in the nicotine industry. Labstat will play a pivotal role in steering the science agenda, with Dr Bonnie Coffa PhD DABT, Labstat’s Scientific Director of Toxicology, leading these efforts.
As part of this partnership, Labstat will help to elevate the profile of GINN across North America and in other countries where it operates. The combined expertise of GINN and Labstat is expected to foster greater innovation and adherence to high standards within the industry, benefiting both consumers and stakeholders.
Michael Bond, President of Labstat International, said:
"The importance of bringing data to bear to ensure balanced decisions are made when it comes to regulations and policies that affect consumers cannot be overstated. This partnership with GINN underscores our commitment to scientific excellence and regulatory integrity. By leading the steering committee on science and standards, we aim to drive forward critical research and set benchmarks that will safeguard consumer interests and enhance product safety.
"At Labstat, we believe that rigorous scientific analysis and transparent data are fundamental to developing fair and effective regulations. Our collaboration with GINN will enable us to work closely with a broad spectrum of industry experts, including scientists, lawyers, manufacturers, businesses, and regulators, to foster a more informed and balanced approach to nicotine product regulation.
"We are excited to take on this leadership role with GINN and look forward to contributing to the advancement of science and standards within the nicotine industry. Our collective efforts will not only improve product safety but also ensure that regulatory policies are grounded in solid scientific evidence."
Shem Baldeosingh, Director of GINN, commented:
"We readily welcome Labstat International as one of the world’s leading nicotine product testing laboratories. Their extensive experience and dedication to scientific rigor make them an invaluable partner in our mission to promote reduced-risk products and informed regulatory practices.
"Labstat's scientific and regulatory stewardship, combined with their collaborative approach, will significantly enhance our efforts to engage with key stakeholders globally. This partnership is a significant step forward in ensuring that our industry adheres to the highest standards of safety and efficacy."
ENDS
Notes to Editors:
For more information or journalist queries, please contact us: [email protected].
About GINN:
The Global Institute for Novel Nicotine (GINN) is dedicated to positioning itself as the industry's primary advocate for non-vaping reduced-risk products. While vapes have established representation, GINN focuses on emerging reduced-risk products like nicotine pouches and heat-not-burn. As a membership-based association, GINN engages with stakeholders globally, and we ensure an evidence-based and science-led approach is at the heart of all that it does.
About Labstat International:
Labstat International Inc. is a leading independent testing laboratory specializing in analytical chemistry, in vitro toxicology, microbiology, and bioanalytical testing for the nicotine industry. With a commitment to scientific excellence and regulatory compliance, Labstat provides comprehensive testing services that support the development and marketing of reduced risk nicotine products, and continues to pioneer advancements in product testing and regulatory standards.
